REFRACTORY THYROID GLAND ONCOCYTIC CARCINOMA

Clinical trials for REFRACTORY THYROID GLAND ONCOCYTIC CARCINOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY THYROID GLAND ONCOCYTIC CARCINOMA trials appear

Sign up with your email to follow new studies for REFRACTORY THYROID GLAND ONCOCYTIC CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New hope for tough thyroid cancers: drug XL092 targets resistant tumors

Disease control Recruiting now

This study tests a new drug called XL092 in people with advanced thyroid cancer that no longer responds to standard radioiodine therapy. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if it can slow or stop the cancer from spreading, an…

Matched conditions: REFRACTORY THYROID GLAND ONCOCYTIC CARCINOMA

Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control

Last updated May 26, 2026 07:20 UTC

REFRACTORY THYROID GLAND ONCOCYTIC CARCINOMA

Get alerted when new REFRACTORY THYROID GLAND ONCOCYTIC CARCINOMA trials appear

New hope for tough thyroid cancers: drug XL092 targets resistant tumors